Lifecare’s Sencell – Miniature implantable glucose sensor
Lifecare's Sencell is a rice-sized, implantable glucose sensor for continuous monitoring. Lasting 6+ months, it tracks analytes in humans and pets.

Lifecare is a medical sensor company whose Sencell monitors glucose continuously for people with diabetes.
lifecare.noCrawled Nov 19, 2026
Lifecare's Sencell is a rice-sized, implantable glucose sensor for continuous monitoring. Lasting 6+ months, it tracks analytes in humans and pets.
Sencell, a 3D-printed nano-sensor, provides real-time glucose monitoring for 6+ months, wirelessly sending data to a smart device for easy glucose control.
Lifecare develops miniaturized sensor tech using nanotechnology to monitor glucose, lactate, and more through osmotic pressure changes.
Lifecare partners with top European R&D organizations to strengthen innovation and access advanced technologies for medical advancements.
Lifecare Veterinary adapts Sencell for pets, set to launch in 2024, providing faster, convenient glucose monitoring for diabetic dogs and cats.
RemovAid, an ISO 13485:2016 certified company, develops CE-approved devices for removing subdermal implants. Lifecare acquired 89.6% of RemovAid in 2024.
Lifecare contributes to scientific research with publications on glucose monitoring technology, including studies in Sensors journal, white papers, and doctoral research.
Following the Rights Issue in June 2024 a total of 4,193,806 warrants (Nw: “frittstående tegningsretter”) are outstanding in Lifecare ASA. The exercise period for the warrants commenced 2 June 2025 and will end 13 June 2025 at 16:30 hours CEST.
Bergen, 30 January 2026 – Lifecare ASA notes that the Norwegian Press Complaints Commission (PFU) has upheld the Company’s complaint concerning media coverage related to Lifecare’s stock exchange announcements.
Redeye interviews Lifecare CEO Joacim Holter to discuss the ongoing development of automated production, the status of its trials, and the company’s perspective on Sencell’s market potential.
The world experiences a record number of people with diabetes. How has diabetes technology evolved over the last 40 years, and how can a Norwegian medtech company contribute to increased patient safety and comfort?
Lifecare manages measurement techniques, including programming and interfacing readout devices at its facilities in Reutlingen, Germany.
Coordinate product development and production preparations in collaboration with the CSO.
The Group management team ensures smooth daily operations and alignment with the company's strategic goals.
Lifecare develops miniaturized, implantable sensors for diabetes management and broader medical applications.
Lifecare is commercializing sensor technology, with a focus on production for the veterinary market and clinical testing for human applications.
Olav Ellingsen discovery a link between glucose levels and osmotic pressure in diabetes led to Lifecare’s Sencell solution.
Lifecare develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers.
Lifecare designs implantable nanobiosensors for continuous glucose and biomarker monitoring.
Lifecare ASA releases its Q3 2026 financial report and operational update, detailing performance for its next-generation Continuous Glucose Monitor (CGM) development. The company highlights progress in its medical sensor technology aimed at improving glucose monitoring solutions. Financial and operational metrics are included in the report for investor review.
Lifecare ASA announces its Q3 2026 financial results will be released on **12 November 2026 at 07:00 CET**, followed by a live webcast at **10:00 CET**. The presentation details the company’s operational and financial performance for the quarter.
Lifecare ASA is scaling up in-house production of continuous glucose monitoring (CGM) implants at its Bergen facilities. The company has completed multiple manufacturing batches in quick succession, shifting more production and testing operations to its Norwegian site. This consolidation strengthens Lifecare’s ability to control implant manufacturing internally.
Morten Foros Krohnstad, Chair of the Board of Lifecare ASA, sells 3,600,000 shares to Ben Va Holding AS at NOK 0.55 per share. The transaction involves a company closely associated with Krohnstad. Lifecare ASA confirms the mandatory notification of the trade by its primary insider.
Lifecare ASA produces its first functional continuous glucose monitoring (CGM) implants in-house at its Bergen facility. The milestone marks progress toward controlled manufacturing of the company’s implantable sensor technology. This development supports Lifecare’s goal of advancing next-generation CGM solutions.
Lifecare ASA acquires 80% of Ocean TuniCell AS, expanding its portfolio in medical technology. The transaction follows a prior stock exchange announcement and involves the issuance of consideration shares as part of the deal. The move strengthens Lifecare’s position in advanced wound care solutions.
Lifecare ASA acquires an 80% stake in Ocean TuniCell AS to gain access to its established **GMP-certified manufacturing infrastructure** in Bergen. The deal secures production capabilities for Lifecare’s operations, leveraging Ocean TuniCell’s existing compliance and facility standards. Terms of the share purchase agreement were announced in August 2026.